Fundraising FoxMonograph Capital Partners — 2023 Investments
3 investments dated 2023 · listed companies and verified rows first · show all
ODAIA offers Marketing Intelligence, a platform for pharmaceutical marketing and sales teams that ties channel-level actions to prescription (Rx) outcomes and coordinates healthcare provider (HCP) engagement across digital and field channels.
AI & Machine LearningDigital HealthHealthtechMarketing TechSaaSSales Tech
Philip Poulidis(Founder)inHelen Kontozopoulos(Founder)
Co-investorsAlumni VenturesGraphite VenturesPanache VenturesStand Up VenturesThreshold VenturesToronto Innovation Acceleration Partners+5 more
Sudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions.
BiotechHealthtechMedical DevicesMenlo Park, US
Jim Bristol(Director)Daniel Estes(Director)inScott Byrd(Executive Officer, Director)in
Co-investorsFrazier Life SciencesPICUS CAPITALSanofi VenturesSV Health InvestorsDementia Discovery FundFrazier Healthcare Partners+2 more
UroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology.
BiotechHealthtechMedical DevicesPrinceton, US
Mark Schoenberg, M.D.(Executive Officer)Liz Barrett(President and Chief Executive Officer)inJason Smith(Executive Officer)Arie Belldegrun, M.D.(Director)Dan Wildman(Director)Don Kim(Executive Officer)
Co-investorsAisling CapitalPontifax Venture CapitalAravis Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.